Supportive Care: 342 Real Stories

342 stories match supportive care. 208 of them mention chemotherapy.

Cancer Stories

Amber, who was diagnosed with Stage III Colorectal CancerColorectal Cancer

Stage III Colorectal Cancer: Amber's Survivor Story

Patient Info: Amber Mike, Female, 40s | Stage III

As of February 2026, Amber had completed Stage III colorectal cancer treatment, was doing well under close monitoring with tumor markers every 3 months, and was rebuilding life through survivorship, therapy, travel, and advocacy.

City of Hope
OutcomeSurvivorship / Surveillance
Natasha, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV Colorectal Cancer: Natasha's Patient Story

Patient Info: Natasha McCants, Female, 40s | Stage IV

Biomarkers: Unspecified tumor mutation identified by molecular testing

Metastatic Site: Liver; lungs; ovary

As of February 2026, Natasha’s Stage IV colorectal cancer was under control after mutation-informed treatment at City of Hope, but Signatera showed potentially active cells and she remained on daily chemotherapy pills.

City of Hope
OutcomeResponding Well
A patient, who was diagnosed with Lung CancerLung Cancer

Pulmonary nocardiosis that mimicked lung cancer in a man with COPD

Patient Info: Anonymized, Male, 70+

Biomarkers: Not applicable; malignancy not found

The lung lesions were ultimately attributed to pulmonary nocardiosis rather than cancer. Symptoms, inflammatory markers, and CT findings improved after pathogen-directed antibiotics, and the patient was discharged stable with follow-up arranged.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Breast CancerBreast Cancer

Triple-negative breast cancer diagnosed during pregnancy: remission

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative

The patient remains in remission 30 months after surgery. Immune-related brachial plexopathy after treatment improved after steroids, IVIG, and plasmapheresis, with electrophysiologic resolution and near-complete strength and sensory recovery.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Stage IV ER-positive/HER2-negative breast cancer with synchronous gastric and bone metastases

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Gastric metastasis showed ER-positive, PR-negative, HER2 0 lobular breast cancer. Breast primary was ER/PR-positive, HER2-negative

Metastatic Site: bone; stomach/gastric

At 2-month follow-up, upper-GI symptoms had improved, anastrozole plus palbociclib was tolerated, and CT showed stable disease with persistent diffuse osseous metastases; no further follow-up was available.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IVB lung adenocarcinoma with severe immune-related complications

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 TPS 20%; BRAF mutation

Metastatic Site: left supraclavicular fossa, left axilla, right hilum,…

The patient had an initial partial response to ipilimumab/nivolumab but developed severe immune-related pneumonitis, thrombocytopenia, and aplastic anemia. Cytopenias recovered with eltrombopag, but lung cancer later relapsed with carcinomatous meningitis, and he died 20 months after diagnosis.

PubMed Central
OutcomeIn Memory
Janet, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Janet's Patient Story

Patient Info: Janet Ayala, Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; ATM mutation

After complete pathologic response and completion of HER2-targeted infusions, Janet remained in survivorship-focused ongoing care with estrogen suppression and additional endocrine/targeted therapy planning to reduce recurrence risk.

City of Hope
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR L858R lung adenocarcinoma with rapid neurologic decline

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: EGFR L858R mutation; CK7-positive; Napsin A-positive; TTF-1-positive; p40-negative; Ki-67 about 1%

Metastatic Site: brain parenchyma and meninges

The patient developed rapidly progressive cognitive decline with multifocal brain lesions. Lung biopsy confirmed EGFR L858R lung adenocarcinoma, and she received amivantamab, but neurologic deterioration continued and she died in the fourth month of the disease course.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

BRAF-mutant stage IV lung adenocarcinoma complicated by immunotherapy-induced diabetes

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: BRAF mutation; GADA-positive during immune-related diabetes evaluation

Metastatic Site: left lower lung, pleural

The patient had Stage IV BRAF V600E-mutant lung adenocarcinoma treated with targeted therapy and later tislelizumab. Immunotherapy was suspended after hypoadrenocorticism and diabetic ketosis; she required ongoing insulin therapy, with persistently low C-peptide at 6-month follow-up.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic triple-negative breast cancer with sacituzumab-govitecan pneumonitis and progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: lung

Sacituzumab-govitecan pneumonitis improved with corticosteroids and half-dose rechallenge did not reproduce pneumonitis, but follow-up CT showed one new pulmonary metastasis and enlargement of previous lung metastases; PFS on sacituzumab govitecan was 5.37 months.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Non-Small Cell Lung CancerLung Cancer

Kidney damage as a rare side effect of durvalumab immunotherapy

Patient Info: Anonymized, Male, 70+

The lung-cancer burden decreased during treatment. Durvalumab was stopped because of nephrotic syndrome, which achieved sustained complete remission with prednisolone.

PubMed Central
OutcomeResponding Well
Maria, who was diagnosed with Colorectal CancerColorectal Cancer

I Survived Childhood Cancer. Then I Was Diagnosed AGAIN at 18.

Patient Info: Maria, Female, Under 40

Biomarkers: Mosaic variegated aneuploidy syndrome 3; prior colon polyp genetic testing negative before final diagnosis

The early colon cancer was removed during colonoscopy, but Maria continues long-term surveillance for recurrent polyps and survivorship effects related to childhood Wilms tumor and MVA3.

The Patient Story
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV non-small cell lung cancer: treatment and follow-up story

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: ALK mutation/rearrangement; EGFR negative

Metastatic Site: Bone, including left humerus

As of January 2026, he described about 3 years on ALK-targeted oral therapy, feeling well, exercising 3-4 times per week, and living close to normal life with Stage IV ALK-positive lung cancer.

YouTube (ZH search)
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Stage IV MSI-H KRAS-mutant colorectal adenocarcinoma: severe pembrolizumab-associated hypercalcemia resolved with steroids and zoledronic acid

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: KRAS G12xa mutation; MSI-H; BRAF wild type; NRAS wild type; PTH low-normal

Metastatic Site: liver

After the second pembrolizumab dose, severe hypercalcemia and electrolyte abnormalities resolved with high-dose glucocorticoids, zoledronic acid, and supportive care; cancer response was not yet described.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

MET exon 14 skipping lung adenocarcinoma: sequential MET-TKI toxicity and ongoing chemotherapy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: MET exon 14 skipping mutation; EGFR negative; ALK negative; ROS1 negative; PD-L1 tumor proportion score 10%

Metastatic Site: pleura

The cancer recurred with pleural dissemination after surgery and adjuvant UFT. Sequential MET inhibitors and systemic therapies provided periods of disease control but were limited by ILD and non-ILD toxicities; at the report, he remained on carboplatin, pemetrexed, and bevacizumab.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage I Invasive Ductal CarcinomaBreast Cancer

Male breast cancer history complicated by suspected bone disease and later IgG-kappa multiple myeloma

Patient Info: Anonymized, Male, 60s | Stage I

Biomarkers: Breast cancer was ER/PR-positive and HER2-negative by FISH. Later workup showed IgG-kappa multiple myeloma with IgH rearrangement.

The patient achieved very good partial response after KBD and completed autologous hematopoietic stem cell transplantation with engraftment, but later died of a novel coronavirus infection.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Breast CancerBreast Cancer

Hormone receptor-positive breast cancer treated with pembrolizumab trial complicated by acquired lipodystrophy

Patient Info: Anonymized, Female, 40s

Biomarkers: HER2-negative breast cancer. Metabolic changes occurred during/after pembrolizumab.

As of December 2025, breast cancer treatment had included neoadjuvant chemotherapy/pembrolizumab, surgery, adjuvant pembrolizumab, and endocrine therapy; CT did not show recurrence during weight-loss evaluation, but she required ongoing metabolic care for pembrolizumab-associated acquired generalized lipodystrophy.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Non-Small Cell Lung CancerLung Cancer

Lung adenocarcinoma with marked eosinophilia and Löffler endocarditis: clinical deterioration after treatment withdrawal

Patient Info: Anonymized, Male, 70+

Biomarkers: Markers supported lung adenocarcinoma with TTF-1 and Napsin-A positivity. Ki-67 ~30%; FGFR1 rearrangement not detected.

The patient deteriorated with severe eosinophilia, Löffler endocarditis, lung adenocarcinoma, bilateral pleural effusions, pneumonia, unstable oxygen saturation, and progressive hypotension; his family twice chose voluntary discharge or withdrawal of care.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Breast AdenocarcinomaBreast Cancer

Breast cancer found during workup for progressive hearing loss and paraneoplastic cochleovestibulopathy

Patient Info: Anonymized, Female, 40s

Biomarkers: Breast cancer was ER ~100% and HER2 2+; CK/CK7/GATA3 supported breast origin. Neuronal autoantibodies were suspected but not identified.

As of December 2025, she remained on endocrine therapy, and serial chest CT at 1-year follow-up showed reduction in right axillary lymph-node size; hearing outcome after cochlear implantation was not assessable.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Colorectal CancerColorectal Cancer

Rectal cancer surgery complicated by postoperative intestinal obstruction and resistant Enterococcus infection

Patient Info: Anonymized, Female, 50s

Biomarkers: No cancer biomarkers reported; wound culture grew Enterococcus gallinarum with intrinsic resistance to vancomycin and several other agents

After postoperative intestinal obstruction and severe intra-abdominal infection, her temperature normalized, infection markers returned to normal, antibiotics were stopped, and she was discharged after clinical improvement for continued post-surgical care.

PubMed Central
OutcomeCare Ongoing